Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-07-10
2007-07-10
Woitach, Joseph (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100, C536S023500, C536S023510, C424S093100, C514S04400A
Reexamination Certificate
active
09843922
ABSTRACT:
Use of a negative-sense RNA virus vector has enabled transfer of nucleic acid into nerve cells. The method of this invention can be used for introducing a gene efficiently into nerve cells including the central nerve tissue in gene therapy, etc.
REFERENCES:
patent: 5631237 (1997-05-01), Dzau et al.
patent: 5789245 (1998-08-01), Dubensky et al.
patent: 6451579 (2002-09-01), Jessee et al.
patent: 6514728 (2003-02-01), Kai et al.
patent: 2002/0100066 (2002-07-01), Nagai et al.
patent: 2003/0008399 (2003-01-01), Jessee et al.
patent: 2003/0053988 (2003-03-01), Renner et al.
patent: 0753202 (1998-09-01), None
patent: 0864645 (1998-09-01), None
patent: 0936531 (1999-08-01), None
patent: 1 186 667 (2002-03-01), None
patent: 2000057327 (2000-02-01), None
patent: WO 97/16539 (1997-05-01), None
patent: 0011834 (2000-03-01), None
patent: WO 00/70070 (2000-11-01), None
patent: WO 01/20989 (2001-03-01), None
Deonarain (1998) Exp. Opin. Ther. Pat., 8(1): 53-69.
Gorecki (2001) Exp. Opin. Emerging Drugs, 6(2): 187-98.
Eck, et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, New York, NY., pp. 77-101.
Lamb, et al (2001) Fundamental Virology, 4th Ed., Lippinocott and Wilkins, New York, NY, p. 691.
Yonemitsu,et al (2002) Surgery, 131(Supp. 1): S261-S268.
Nakanishi, et al. (1999) Mol. Membr. Biol., 16: 123-27.
Hasan, et al. (1997) 78: 2813-20.
Crystal (1995) Science, 270: 404-410.
Gura (1997) Science, 278: 1041-42.
Mandel, et al. (2003) CNS Drugs, 17(10): 729-62.
Nobuyuki, et al. (2004) Trends in Genetics, 20(11): 563-69, pp. 563-64, paragraph bridging.
Clements, et al. (1993) Oncogene, 8(5): 1311-16.
Srinivasula, et al. (1996) Proc. Natl. Acad. Sci., USA., 93: 14486-91.
Duckett, et al. (1996) EMBO. J., 15(11): 2685-94.
Hudgins, et al. (1998) Exp. Neurol., 150: 171-82.
Hearn, et al. (1998) Dev. Biol., 197: 93-105.
Schendel, et al. (1997) Proc. Natl. Acad. Sci., USA., 94: 5113-18.
Datta, et al. (1997) J. Biol. Chem., 272(3): 1965-69.
Kobayashi, et al. (1997) Exp. Brain Res., 116: 315-25.
Teng, et al. (1998) Euro. J. Neurosci., 10: 798-802.
Winkler, et al. (1998) Brain Res., 788: 1-12.
Calain, et al. (1993) J. Virol., 67(8): 4822-30.
Sakai, et al. (1999) FEBS Lett., (1999) 456: 221-26.
Anderson, W. F.,Nature, 292(6679 Suppl): 25-30 (1998).
Verma, I.M. et al.,Nature, 389(6648): 239-242 (1997).
Palu, G. et al.,Journal of Biotechnology, 68(1): 1-13 (1999).
Crystal, R.G.,Science, 270(5235): 404-410 (1995).
Gura, T.,Science, 278(5340): 1041-1042 (1997).
Grifman M., et al., “Functional redundancy of acetylcholinesterase and neuroligin in mammalian neuritogenesis”,Proc. Natl. Acad. Sci. USA, 95(23), pp. 13935-13940 (1998).
De Fiebre CM, et al.,Neurochem.18(10): 1089-94 (1993).
Nakanishi M, et al.J. Control Release54(1): 61-8 (1998).
Miyazaki, H., et al., “Glial Cell Lin-Derived Neurotrophic Factor Protects Against Delayed Neuronal Death After Transient Forebrain Ischemia In Rats”,Neuroscience, 89 (3), 643-647 (1999).
Oomura, Y., “Physiological Effects of Endogenous Satiety Substances on Brain,” Inst. Of Bio-Active Science, Nippon Zoki Pharmaceutical (1998); 20: 567-575 (with English explanation).
Wu P., et al., “Sendai virosomal infusion of an adeno-associated virus derived construct containing neuropeptide Y into primary rat brain cultures,” Neuroscience Letters 1995; 190: 73-76.
Co-pending U.S. Appl. No. 11/178,978, inventors Fukumura, M., et al., filed Jul. 12, 2005 (Not Published).
H. Yoshiura, et al “Internet-Marks: Clear, secure and portable visual marks for cyber worlds”, Lecture Notes in Computer Science, Springer Verlag, NY, vol. 1796, May 17, 2000, pp. 195-202.
De Fiebre, C.M. et al. “Differential Adenoassociated Virus Vector-Driven Expression of a Neuropeptide Y Gene in Primary Rat Brain Astroglial Cultures after Transfection with Sendai Virosomes Versus Lipofection™,”Neurochem. Res. 19:643-648, Plenum Publishing Corporation (1994).
Kato, A. et al., “Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense,”Genes to Cells 1:569-579, Blackwell Science Limited (1996).
Moriya, C. et al., “Large quantity production with extreme convenience of human SDF-1α and SDF-1β BY A Sendai virus vector,”FEBS Letts. 425:105-111, Federation of European Biochemical Societies (1998).
Suzuki, J.-I. et al., “Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide,”Nature Med. 3:900-903, Nature Publishing Group (1997).
Yamada, K. et al., “Efficient oligonucleotide delivery using the HVJ-liposome method in the central nervous system,”Am. J. Physiol. 271:R1212-1220, American Physiological Society (1996).
U.S. Appl. No. 09/762,641, entitled “RNA Virus Vector with Contact Infiltration Capability,” 30 pages (unpublished).
Office Action mailed Oct. 25, 1999, for U.S. Appl. No. 09/070,938, Nagai, Y., et al., filed Apr. 30, 1998.
Office Action mailed Feb. 16, 2000, for U.S. Appl. No. 09/070,938, Nagai, Y., et al., filed Apr. 30, 1998.
Office Action mailed Nov. 21, 2000, for U.S. Appl. No. 09/070,938, Nagai, Y., et al., filed Apr. 30, 1998.
Office Action mailed Dec. 6, 2001, for U.S. Appl. No. 09/070,938, Nagai, Y., et al., filed Apr. 30, 1998.
Office Action mailed Jan. 15, 2002, for U.S. Appl. No. 09/070,938, Nagai, Y., et al., filed Apr. 30, 1998.
Office Action mailed Jan. 13, 2003, for U.S. Appl. No. 09/070,938, Nagai, Y., et al., filed Apr. 30, 1998.
Office Action mailed Mar. 18, 1999, for U.S. Appl. No. 09/071,591, Nagai, Y., et al., filed May 1, 1998.
Office Action mailed Dec. 3, 1999, for U.S. Appl. No. 09/071,591, Nagai, Y., et al., filed May 1, 1998.
Office Action mailed Aug. 21, 2000, for U.S. Appl. No. 09/471,840, Nagai, Y., et al., filed Dec. 23, 1999.
Office Action mailed May 10, 2001, for U.S. Appl. No. 09/471,840, Nagai, Y., et al., filed Dec. 23, 1999.
Office Action mailed Dec. 6, 2001, for U.S. Appl. No. 09/471,840, Nagai, Y., et al., filed Dec. 23, 1999.
Office Action mailed Jan. 15, 2002, for U.S. Appl. No. 09/471,840, Nagai, Y., et al., filed Dec. 23, 1999.
Office Action mailed Jan. 13, 2003, for U.S. Appl. No. 09/471,840, Nagai, Y., et al., filed Dec. 23, 1999.
Office Action mailed Apr. 11, 2002, for U.S. Appl. No. 09/720,003, Akuta, T., et al., filed Sep. 4, 2001.
Office Action mailed Feb. 25, 2003, for U.S. Appl. No. 09/720,003, Akuta, T., et al., filed Sep. 4, 2001.
Office Action mailed Jan. 17, 2003, for U.S. Appl. No. 09/720,979, Fukumura, M., et al., filed Mar. 7, 2001.
Office Action mailed Jun. 8, 2004, for U.S. Appl. No. 09/720,979, Fukumura, M., et al., filed Mar. 7, 2001.
Office Action mailed Jan. 24, 2002, for U.S. Appl. No. 09/728,207, Nagai, Y., et al., filed Dec. 1, 2000.
Office Action mailed Oct. 18, 2002, for U.S. Appl. No. 09/728,207, Nagai, Y., et al., filed Dec. 1, 2000.
Office Action mailed Jul. 14, 2003, for U.S. Appl. No. 09/728,207, Nagai, Y., et al., filed Dec. 1, 2000.
Office Action mailed Nov. 4, 2003, for U.S. Appl. No. 09/728,207, Nagai, Y., et al., filed Dec. 1, 2000.
Office Action mailed Aug. 5, 2004, for U.S. Appl. No. 09/728,207, Nagai, Y., et al., filed Dec. 1, 2000.
Asakawa Makoto
Fukumura Masayuki
Hasegawa Mamoru
Shirakura Masayuki
DNAVEC Research Inc.
Kelly Robert M.
Sterne Kessler Goldstein & Fox P.L.L.C.
Woitach Joseph
LandOfFree
Sendai viral vectors comprising foreign genes inserted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sendai viral vectors comprising foreign genes inserted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sendai viral vectors comprising foreign genes inserted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3809967